#157981

DLKP-pHA MDR 1/A cell line

Cat. #157981

DLKP-pHA MDR 1/A cell line

Cat. #: 157981

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Lymph Node

Disease: Cancer

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Martin Clynes

Institute: Dublin City University

Tool Details
Handling

Tool Details

*FOR RESEARCH USE ONLY

  • Name: DLKP-pHA MDR 1/A cell line
  • Cancer: Lung cancer
  • Cancers detailed: Lung carcinoma
  • Research fields: Cancer;Cell biology;Drug development
  • Tool sub type: Continuous
  • Parental cell: DLKP
  • Organism: Human
  • Tissue: Lymph Node
  • Disease: Cancer
  • Growth properties: monolayer, slow-growing
  • Conditional description: fold resistance comp. toÂ?‚ DLKP parent: 15-fold Adriamycin; 12.2 Vincristin; 13.6 VP-16 (Etoposide).
  • Description: heterogeneous lung carcinoma population. Epithelial model
  • Production details: DLKPÂ?‚ transfected with a pHaMDR1/A plasmid (full cDNA for human MDR1 gene) and treated with 50mg/ml adriamycin
  • Biosafety level: 1
  • Recommended controls: DLKP parental line

Handling

  • Format: Frozen
  • Growth medium: DMEM/Ham's F12, 5% FCS supplement with 50ng/ml adriamycin at least once/week. Passage 2-3 time weekly, spin after trypsinisation. Freezing: 5% DMSO, freeze at 2x10(6) cells/ml, spin down after reviving
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes